Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Cipla
Daiichi Sankyo
Queensland Health
Covington
Baxter
Fish and Richardson
Cantor Fitzgerald
Julphar

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,256,216 protect, and when does it expire?


Patent ► Subscribe protects NEURONTIN and is included in one NDA.

Protection for NEURONTIN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: ► Subscribe

Title:Liquid pharmaceutical compositions
Abstract:A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.
Inventor(s): Kulkarni; Neema M. (Randolph, NJ), Schneider; Michael (Denzlingen, DE), Silbering; Steven B. (Forest Hills, NY), Meyer-Wonnay; Hans (Emmendingen, DE), Sanii-Yahyai; Nahid (Ann Arbor, MI)
Assignee: Warner-Lambert Company LLC (
Application Number:10/602,215
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Parke Davis
NEURONTIN
gabapentin
SOLUTION;ORAL021129-001Mar 2, 2000AARXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Cantor Fitzgerald
Teva
McKinsey
Dow
Cipla
Covington
UBS
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot